Skip to main content

A genomic analysis of metastases-prone localized prostate cancer identifies AZIN1 as driver of metastatic progression.

Van den Broeck
Thomas
Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine
KU Leuven
Leuven
Belgium
Show all authors
Gevaert
Thomas
Urology
University Hospitals Leuven, KU Leuven
Leuven
Belgium
Prekovic
Stefan
Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine
KU Leuven
Leuven
Belgium
Ong
Kaye
GenomeDx Biosciences
Vancouver, BC
Canada
Tosco
Lorenzo
Urology
University Hospitals Leuven, KU Leuven
Leuven
Belgium
Moris
Lisa
Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine
KU Leuven
Leuven
Belgium
Smeets
Elien
Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine
KU Leuven
Leuven
Belgium
Lehrer
Jonathan
GenomeDx Biosciences
Vancouver, BC
Canada
Haddad
Zaid
GenomeDx Biosciences
Vancouver, BC
Canada
Helsen
Christine
Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine
KU Leuven
Leuven
Belgium
Lambrechts
Diether
Laboratory for Translational Genetics
KU Leuven
Leuven
Belgium
Boeckx
Bram
Laboratory for Translational Genetics
KU Leuven
Leuven
Belgium
Margrave
Jennifer
GenomeDx Biosciences
Vancouver, BC
Canada
Van Poppel
Hendrik
Urology
University Hospitals Leuven, KU Leuven
Leuven
Belgium
Everaerts
Wouter
Urology
University Hospitals Leuven, KU Leuven
Leuven
Belgium
Erho
Nicholas
GenomeDx Biosciences
Vancouver, BC
Canada
Buerki
Christine
GenomeDx Biosciences
Vancouver, BC
Canada
Davicioni
Elai
GenomeDx Biosciences
Vancouver, BC
Canada
Claessens
Frank
Laboratory of Molecular Endocrinology, Department of Cellular and Molecular Medicine
KU Leuven
Leuven
Belgium
Joniau
Steven
Urology
University Hospitals Leuven, KU Leuven
Leuven
Belgium

Tabs

Speciality: 
Urology
Keywords: 
AZIN1, localized prostate cancer, High-risk Prostate cancer, radical prostatectomy